Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRUG NASDAQ:DSGN NASDAQ:IMDX NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$60.95-1.0%$81.58$23.17▼$123.75$593.18M-5.53397,187 shs658,916 shsDSGNDesign Therapeutics$10.97+4.2%$12.30$3.33▼$17.25$685.15M1.631.30 million shs562,645 shsIMDXOncocyte$5.61+3.3%$4.86$2.33▼$8.51$181.15M1.79288,683 shs389,868 shsSLDBSolid Biosciences$7.14-1.1%$7.37$3.79▼$8.87$702.93M2.431.11 million shs1.66 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences-1.01%-11.67%-27.94%-15.35%+119.64%DSGNDesign Therapeutics+4.18%+3.00%-29.77%+8.40%+181.28%IMDXOncocyte+3.31%+7.06%+10.00%+14.26%+560,999,900.00%SLDBSolid Biosciences-1.11%+6.57%-3.25%-2.33%+54.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$60.95-1.0%$81.58$23.17▼$123.75$593.18M-5.53397,187 shs658,916 shsDSGNDesign Therapeutics$10.97+4.2%$12.30$3.33▼$17.25$685.15M1.631.30 million shs562,645 shsIMDXOncocyte$5.61+3.3%$4.86$2.33▼$8.51$181.15M1.79288,683 shs389,868 shsSLDBSolid Biosciences$7.14-1.1%$7.37$3.79▼$8.87$702.93M2.431.11 million shs1.66 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences-1.01%-11.67%-27.94%-15.35%+119.64%DSGNDesign Therapeutics+4.18%+3.00%-29.77%+8.40%+181.28%IMDXOncocyte+3.31%+7.06%+10.00%+14.26%+560,999,900.00%SLDBSolid Biosciences-1.11%+6.57%-3.25%-2.33%+54.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRUGBright Minds Biosciences 2.86Moderate Buy$143.83135.99% UpsideDSGNDesign Therapeutics 2.88Moderate Buy$16.5050.41% UpsideIMDXOncocyte 2.00Hold$12.00113.90% UpsideSLDBSolid Biosciences 2.92Moderate Buy$17.00138.10% UpsideCurrent Analyst Ratings BreakdownLatest IMDX, DRUG, DSGN, and SLDB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026SLDBSolid Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.006/1/2026DRUGBright Minds Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$145.005/20/2026DRUGBright Minds Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $220.005/13/2026SLDBSolid Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$17.00 ➝ $18.005/13/2026SLDBSolid Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $16.005/12/2026DSGNDesign Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/4/2026DSGNDesign Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $21.004/29/2026DSGNDesign Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.004/27/2026SLDBSolid Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026SLDBSolid Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DSGNDesign Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRUGBright Minds BiosciencesN/AN/AN/AN/A$8.33 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/AIMDXOncocyte$4.05M44.73N/AN/A($1.10) per share-5.10SLDBSolid BiosciencesN/AN/AN/AN/A$2.28 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRUGBright Minds Biosciences-$8.74M-$2.44N/AN/AN/AN/A-20.58%-20.25%8/13/2026 (Estimated)DSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)IMDXOncocyte-$50.22M-$1.48N/AN/AN/A-2,454.64%N/A-96.96%N/ASLDBSolid Biosciences-$174.32M-$1.95N/AN/AN/AN/A-73.42%-61.13%8/11/2026 (Estimated)Latest IMDX, DRUG, DSGN, and SLDB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q2 2026DRUGBright Minds Biosciences-$0.8633-$0.80+$0.0633-$0.80N/AN/A5/13/2026Q1 2026IMDXOncocyteN/A-$0.28N/A-$0.12N/A$0.03 million5/12/2026Q1 2026SLDBSolid Biosciences-$0.40-$0.52-$0.12-$0.52N/AN/A4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/A3/26/2026Q4 2025IMDXOncocyteN/A-$0.27N/A-$0.72N/A$1.14 million3/19/2026Q4 2025SLDBSolid Biosciences-$0.51-$0.50+$0.01-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRUGBright Minds BiosciencesN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AIMDXOncocyteN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRUGBright Minds BiosciencesN/A81.4781.47DSGNDesign TherapeuticsN/A22.2822.28IMDXOncocyteN/A2.542.51SLDBSolid BiosciencesN/A13.1013.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRUGBright Minds Biosciences40.52%DSGNDesign Therapeutics56.64%IMDXOncocyte55.35%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipDRUGBright Minds Biosciences42.66%DSGNDesign Therapeutics17.10%IMDXOncocyte2.05%SLDBSolid Biosciences2.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableDSGNDesign Therapeutics4062.46 million51.78 millionOptionableIMDXOncocyte12032.29 million31.63 millionN/ASLDBSolid Biosciences10098.45 million95.83 millionOptionableIMDX, DRUG, DSGN, and SLDB HeadlinesRecent News About These CompaniesSolid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 6, 2026 | americanbankingnews.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comSolid Biosciences to Participate at Upcoming Investor ConferencesJune 1, 2026 | globenewswire.comJ.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)May 24, 2026 | theglobeandmail.comWhere Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?May 20, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)May 14, 2026 | theglobeandmail.comSolid Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 12, 2026 | globenewswire.comSolid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular DystrophyMay 7, 2026 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comSolid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell TherapyApril 30, 2026 | globenewswire.comSolid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular DystrophyApril 28, 2026 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB)April 17, 2026 | theglobeandmail.comSolid Biosciences Adjusts Board Classes in Governance MoveApril 12, 2026 | theglobeandmail.comSolid Biosciences to Participate at Upcoming Investor ConferencesApril 7, 2026 | globenewswire.comJ.P. Morgan Issues a Buy Rating on Solid Biosciences (SLDB)March 27, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Mereo Biopharma Group Plc (MREO)March 22, 2026 | theglobeandmail.comGuggenheim initiates coverage of Solid Biosciences (SLDB) with buy recommendationMarch 21, 2026 | msn.comSolid Bio wins new buy at Guggenheim on lead assetMarch 20, 2026 | msn.comSolid Biosciences Inc.: Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 20, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Best Growth Stocks for the Next 10 YearsBy Chris Markoch | May 31, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026Biogen Stock Slides After Trial Miss, But Analysts Stay BullishBy Chris Markoch | May 22, 2026Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyBy Chris Markoch | May 23, 2026IMDX, DRUG, DSGN, and SLDB Company DescriptionsBright Minds Biosciences NASDAQ:DRUG$60.95 -0.62 (-1.01%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$60.63 -0.32 (-0.53%) As of 06/12/2026 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Design Therapeutics NASDAQ:DSGN$10.97 +0.44 (+4.18%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$10.96 -0.01 (-0.05%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Oncocyte NASDAQ:IMDX$5.61 +0.18 (+3.31%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$5.62 +0.01 (+0.27%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Solid Biosciences NASDAQ:SLDB$7.14 -0.08 (-1.11%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$7.15 +0.01 (+0.11%) As of 06/12/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
